公开(公告)号：CA2737241C

公开(公告)日：2017-08-29

申请号：CA2737241

申请日：2009-09-25

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  HANCOCK LAURA ,  HEYWOOD SAM PHILIP

IPC: C07K16/46 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab' fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab' fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.

公开(公告)号：MY162790A

公开(公告)日：2017-07-14

申请号：MYPI2013701205

申请日：2012-01-11

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/24

Abstract: THE INVENTION RELATES TO ANTIBODY MOLECULES HAVING SPECIFICITY FOR ANTIGENIC DETERMINANTS OF BOTH IL-17A AND IL-17F, THERAPEUTIC USES OF THE ANTIBODY MOLECULES AND METHODS FOR PRODUCING SAID ANTIBODY MOLECULES.

公开(公告)号：BRPI0918947A2

公开(公告)日：2015-12-01

申请号：BRPI0918947

申请日：2009-09-25

Applicant: UCB PHARMA SA

Inventor： HANCOCK LAURA ,  ADAMS RALPH ,  HEYWOOD SAM PHILIP

IPC: C07K16/24 ,  C07K16/18 ,  C07K16/28 ,  C07K16/46

公开(公告)号：TN2013000292A1

公开(公告)日：2015-01-20

申请号：TN2013000292

申请日：2013-07-10

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/24

公开(公告)号：PE20141995A1

公开(公告)日：2014-12-06

申请号：PE2014000673

申请日：2012-11-09

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILLIP ,  HUMPHREYS DAVID PAUL

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/44 ,  C07K16/46

Abstract: SE REFIERE A UNA PROTEINA DE FUSION QUE ES UN ANTICUERPO BIESPECIFICO, LA CUAL SE UNE A OX40 HUMANO Y A ALBUMINA DE SUERO HUMANO, QUE COMPRENDE: UNA CADENA PESADA QUE TIENE, EN SECUENCIA DESDE EL EXTREMO N-TERMINAL, UN PRIMER DOMINIO VARIABLE DE LA CADENA PESADA (VH1), UN DOMINIO CH1 Y UN SEGUNDO DOMINIO VARIABLE DE LA CADENA PESADA (VH2); Y UNA SEGUNDA CADENA LIGERA QUE TIENE, EN SECUENCIA DESDE EL EXTREMO N-TERMINAL, UN PRIMER DOMINIO VARIABLE DE LA CADENA LIGERA (VL1), UN DOMINIO CL Y UN SEGUNDO DOMINIO VARIABLE DE LA CADENA LIGERA (VL2). SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, QUE ES UTIL PARA EL TRATAMIENTO DE UN TRASTORNO PATOLOGICO QUE ESTA MEDIADO POR OX40.

公开(公告)号：ME01810B

公开(公告)日：2014-09-20

申请号：MEP3314

申请日：2005-11-16

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE ,  RAPECKI STEPHEN EDWARD ,  TICKLE SIMON PETER

IPC: A61K39/395 ,  A61K47/48 ,  A61P43/00 ,  C07K14/54 ,  C07K16/24 ,  C12N5/16 ,  C12N15/13 ,  C12N15/63

公开(公告)号：CO7010784A2

公开(公告)日：2014-07-31

申请号：CO14099147

申请日：2014-05-08

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILLIP ,  HUMPHREYS DAVID PAUL

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/44 ,  C07K16/46

公开(公告)号：ES2456669T3

公开(公告)日：2014-04-23

申请号：ES05803526

申请日：2005-11-16

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE ,  RAPECKI STEPHEN EDWARD ,  TICKLE SIMON PETER

IPC: C07K16/24 ,  A61K39/395 ,  A61K47/48 ,  A61P43/00 ,  C07K14/54 ,  C12N5/16 ,  C12N15/13 ,  C12N15/63

Abstract: Un anticuerpo neutralizante que tiene especificidad para IL-17 humana, con una cadena pesada que comprende la secuencia gH11 (SEC ID Nº: 11) y una cadena ligera que comprende la secuencia gL3 (SEC ID Nº: 13).

公开(公告)号：AU2007311689B2

公开(公告)日：2013-05-16

申请号：AU2007311689

申请日：2007-10-18

Applicant: UCB PHARMA SA

Inventor： POPPLEWELL ANDREW GEORGE ,  ADAMS RALPH ,  RAPECKI STEPHEN EDWARD

IPC: C07K16/24 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C12N15/13

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：AU2013203712A1

公开(公告)日：2013-05-02

申请号：AU2013203712

申请日：2013-04-11

Applicant: BIOGEN MA INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE ,  TAYLOR FREDERICK R ,  HSU YEN-MING ,  SU LIHE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: Abstract This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions. FIGURE 19: inhibition of IgG Immune Response to Tetanus Toxoid in Cynomolgus Monkeys Primary Immune Response to TT -